Pharmaceuticals sales
NHS Left Shift Part 4: What Top Gun Maverick Gets Surprisingly Right About the NHS
Every now and then, life hands you something quite rare, a bit of proper downtime. Recently, I found myself in exactly that position. No meetings, no calls, no slides to finish, no proposals to review. Just a quiet evening and the luxury of choosing something to watch without simultaneously answering emails. I decided to escape…
Read MoreWhy strong NHS market access strategies fail to land – and what the system is actually responding to
Free webinar for pharmaceutical, medtech and device teams Selling to the NHS is never as simple as having a great product and waiting for the system to recognise it. You can have a project that makes complete sense. The clinical case is strong, the pathway benefit is obvious and the clinicians you speak to can…
Read MoreThe Real Mythbuster: Why Saying “No” to Higher Drug Prices Won’t Fix The NHS/Pharma Relationship
I’ve just read a very interesting article in the Health Service Journal entitled: The mythbuster: Just say ‘no’ to demands for higher drug prices (registration required to read full piece). Author Steve Black opens with a comparison between pharmaceutical patents and copyright extensions in the entertainment industry, arguing that both primarily enrich large corporations rather…
Read MoreIf I Were On The Board Of An NHS Provider, Here Are Three Questions I Would Be Asking
The NHS has never been under more financial, operational and workforce pressure. Providers are expected to deliver more care, more quickly, with fewer resources. Waiting lists are stubbornly high, staff morale is low and deficits are growing. National policy talks of “recovery” and “productivity gains,” but at the level of individual providers, the reality is…
Read MoreAdvice And Guidance (A&G) – What Are The Opportunities For Pharma?
Advice and Guidance (A&G) is fast becoming one of the most important levers in NHS elective recovery. By allowing GPs to seek specialist advice before making a referral, through platforms such as e-RS or Consultant Connect, it helps patients get quicker answers, reduces unnecessary GP and outpatient appointments and frees up capacity. Ministers claim more…
Read MoreThe workforce challenge: The NHS cannot transform without addressing its people problem
The NHS 10-Year Plan rightly recognises the future of healthcare cannot be delivered without a fit for purpose workforce. In Chapter 7, the focus turns to the people who power the system. It offers a vision for a sustainable, flexible, purpose driven workforce that is not only large enough, but equipped to deliver more preventative,…
Read MoreThe NHS 10-Year Plan: Strategic Vision or Delivery Dilemma?
After working through all ten chapters of the NHS 10-Year Plan, one thing is clear, this is a plan with vision. It offers a compelling picture of a more integrated, preventive, community based NHS, rooted in neighbourhood teams, powered by data and innovation and focused on population health and outcomes. But it’s also a plan…
Read MoreWant To Get Your Pharma Or Medtech Offer Adopted by the NHS in 2025? My New Newsletter Can Help Light The Way
The NHS has battled for years to find its footing after the Covid pandemic, and finally, it feels like there’s a foundational shift in progress. If you’re working in pharma, medtech or devices, you’ve almost certainly felt it; new government, radical ideas, repositioned priorities. The new NHS 10-Year Plan, for example, lays out a vision…
Read MoreCatching Our Breath: NRAP Report Is A Call for Action for Industry Partners
The 2025 National Respiratory Audit Programme (NRAP) State of the Nation Report, aptly titled Catching Our Breath, delivers a sobering and urgent assessment of respiratory care in England and Wales. While acknowledging some improvements, the report reveals profound inequities, service fragmentation and systemic pressures that continue to cost lives and strain NHS capacity. It also…
Read MoreMedicines optimisation: Spotlighting suboptimal treatment and prevention led investment
Previously, I challenged the idea that the prescribing budget should be managed as a cost centre. I argued instead for medicines to be seen as strategic investments that deliver long term system value through better outcomes, fewer non-elective admissions and improved patient outcomes. But if we truly want to unlock the potential of medicines optimisation,…
Read More